Full-Time
Medical Director
Structural Heart
Posted on 12/13/2025
Johnson & Johnson
10,001+ employees
Global healthcare company offering pharma, devices.
Compensation Overview
$160k - $276k/yr
Irvine, CA, USA
Hybrid
 Medical, Clinical & Veterinary (2) |
|---|
| , |
- A degree in medicine (MD, Doctor of Medicine, or DO, Doctor of Osteopathic Medicine) with training in Interventional Cardiology is required.
- Minimum of 10 years of relevant experience in structural heart interventions or related studies is required.
- Cardiovascular industry and structural heart interventions knowledge is strongly preferred and required to have the ability to learn complex technology/clinical applications.
- Significant experience with clinical research is required.
- Strong leadership skills and demonstrated ability to build successful relationships with internal and external partners globally is required.
- Previous people management experience is required.
- Must be able to collaborate well with multiple partners and work effectively in a matrix environment.
- Ability and willingness to travel up to 35% of the time (domestic and international) is required.
- Lead the support for all clinical studies for regulatory purposes and physician initiated collaborative studies, including case support plan and execution, physician training, internal field training, training materials, data analysis, publication support, and data collection for platform claims.
- Contribute to development and execution of product and procedural evidence generation and dissemination strategies for company sponsored and investigator initiated research.
- Collaborate with Preclinical Research and Clinical Research teams to develop global strategies for evidence generation to support regulatory approval/clearance, health technology assessment, customer access, and post-marketing support.
- Provide scientific oversight for clinical trial concept, design, analysis, and reporting in assigned areas.
- Develop materials for study execution (investigator brochures, training materials, etc.).
- Work with Medical Safety to review, trend, and escalate adverse events from clinical studies.
- Provide scientific input and analysis of study results.
- Prepare reports on clinical investigations for regulatory submissions and publications to meet evidence requirements.
- Oversee medical content of internal product documentation and regulatory submissions for new products and renewals.
- Safeguard patient safety.
- Review and approve educational, promotional, and reporting materials for internal stakeholders.
- Strategize and prioritize publication proposals in collaboration with Clinical Science.
- Engage with cross-functional teams including R&D, Clinical Research, Business Development, Regulatory Affairs, Quality & Compliance, Health Economics & Market Access, and Professional Medical Education to influence regulatory and commercial strategy and support product development, studies, safety assessments, and product launches.
- Take leadership roles in governance forums and participate in cross-functional product core teams, safety and quality reviews.
- Support commercial launch of the platform by activating sites, providing physician training, and collecting feedback on product performance and improvements.
- Provide medical and scientific insights to Marketing, R&D, Communications, Legal, Quality Assurance, Risk Management, Product Safety, and Commercial teams to guide strategic direction and tactical activities.
- Engage Key Opinion Leaders, professional societies, payers, and providers to understand trends and insights for product innovation.
- Develop relationships with top academic leaders researching structural heart interventions.
- Collaborate with other functions interacting with structural heart intervention customers/physicians.
- Willingness to travel up to 35% domestically and internationally.
- Relevant business experience in product development for Structural Heart Interventions is highly desired.
- Cardiovascular industry knowledge strongly preferred with proven ability to learn complex technology/clinical applications is preferred.
- Demonstrated capability and success in medical data generation, interpretation, and publications is highly preferred.
- Experience in product risk evaluation and mitigation is preferred.
- Demonstrated success in building teams to meet global needs is preferred.
Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.
Company Size
10,001+
Company Stage
IPO
Headquarters
New Brunswick, New Jersey
Founded
1886
Simplify's Take
What believers are saying
- Q1 2026 revenue hit $24.1 billion, up 9.9%, raising 2026 forecast to $100.8 billion.
- Nipocalimab gains FDA Priority Review for autoimmune hemolytic anemia and myasthenia gravis efficacy.
- Shockwave C2 Aero launches in US and Japan targeting 315 million calcified CAD patients.
What critics are saying
- Stelara sales plunge 60% to $656 million in Q1 2026 post-patent expiration, creating $2.3 billion hole.
- Icotyde stalls at 1,500 prescriptions, missing oncology targets by Q3 2026.
- CAPLYTA faces Invega Sustenna competition, achieving under 10% adoption by mid-2027.
What makes Johnson & Johnson unique
- J&J unites Innovative Medicine and MedTech under single brand since September 2023.
- DARZALEX and TREMFYA dominate oncology and immunology with $57 billion pharma sales in 2024.
- CARTO System leads electrophysiology for 30 years with AI-powered CARTOSOUND SONATA.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Remote Work Options
Performance Bonus
Company News
Johnson & Johnson's Spravato reported $468 million in first-quarter 2026 sales, up 46% year over year, signalling potential for psychedelics-focused companies like AtaiBeckley Inc., according to Jefferies analysts. The esketamine nasal spray, approved for treatment-resistant depression, is on track to reach an annualised run rate exceeding $1.9 billion. Jefferies maintained that Spravato could hit $3 billion in annual sales by 2027 and $5 billion at peak. Over 200,000 patients have been treated globally, up from 140,000 at the start of 2025. Analysts said Spravato's commercial success demonstrates psychedelics can succeed in mainstream healthcare, with existing treatment infrastructure potentially easing adoption of emerging therapies. They highlighted ATAI's intranasal candidate BPL-003 as fitting seamlessly into Spravato's treatment paradigm.
Johnson & Johnson reported 6.4% operational sales growth in Q1 2026, raising full-year guidance to $100.2 billion — the first time the company has reached the $100 billion milestone. The company reaffirmed expectations for double-digit revenue growth by decade's end. Innovative Medicine grew 7.4%, driven by 10 double-digit growing brands including DARZALEX and TREMFYA, despite a 61.7% decline in STELARA due to biosimilar competition. MedTech posted 4.6% growth, led by heart recovery and electrophysiology divisions. The company successfully launched ICOTYDE, the first oral IL-23 peptide for immunology. Management is progressing a $55 billion US manufacturing and R&D investment through 2029, with $12 billion already deployed. The planned separation of its DePuy Synthes Orthopaedics business targets mid-2027 completion.
Johnson & Johnson has launched VARIPULSE Pro in Europe following CE Mark approval, advancing its pulsed field ablation portfolio for treating atrial fibrillation. The system features a new pulse sequence that operates five times faster than its predecessor whilst maintaining equivalent lesion quality. VARIPULSE Pro integrates with the CARTO 3 mapping system and offers a lower temperature profile whilst preserving the platform's established safety and effectiveness profiles. The company is conducting the VARIPURE multicentre study to generate clinical evidence during the commercial launch phase. The technology addresses atrial fibrillation, the most common cardiac arrhythmia affecting over 50 million people worldwide. Johnson & Johnson will showcase VARIPULSE Pro at the European Heart Rhythm Association annual meeting, with 12-month interim study results to be presented. The device is not currently approved in the United States.
Johnson & Johnson has raised $120 million in a Series C round led by Ribbit Capital, valuing the company at $1.45 billion. Sequoia and Kleiner Perkins participated, with Emerson Collective joining as a new backer. The pre-revenue company is developing "Mathematical Superintelligence", an AI system focused on advanced reasoning that claims to eliminate hallucinations by requiring outputs in Lean4 programming language. Its flagship model, Aristotle, achieved top-level performance at the International Mathematical Olympiad in July. Founded in 2023, Harmonic has raised $295 million across three funding rounds in 14 months. The company currently offers Aristotle via a free API and plans to commercialise in safety-critical industries like aerospace and finance.
Nanobiotix has transferred full operational and financial responsibility for its NBTXR3 radioenhancer programme to Johnson & Johnson, with Phase III head-and-neck results expected in H1 2027 and Phase II lung cancer data anticipated in early 2027. The company is pivoting towards its Curadigm nanoprimer platform, filing four patents, starting GMP manufacturing and signing over 20 material transfer agreements with partners. Additional Curadigm data is expected before summer's end. An amended Janssen licence removing most Phase III funding obligations, combined with a royalty financing of up to $71 million, extends Nanobiotix's cash runway into early 2028. The company reported EUR 32.6 million revenue in 2025, reduced R&D spending to EUR 23.1 million, and EUR 52.8 million cash at year-end.